[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639988":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":21,"locations":21,"responsibleParty":29,"collaborators":21,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":21,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":21,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":21,"overallStatus":51,"whyStopped":21,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":21},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-8527 + Rifampin","EXPERIMENTAL","Participants receive single doses of MK-8527 alone and in combination with daily doses of rifampin.",[13,14],"Drug: MK-8527","Drug: Rifampin",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","MK-8527","Administered orally",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"Rifampin",[9],[26],{"name":27,"affiliation":5,"role":28},"Medical Director","STUDY_DIRECTOR",{"type":30,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100639988","phase-1-a-clinical-trial-of-mk-8527-and-rifampin-in-adult-participants-with-latent-tuberculosis-infection-mk-8527-019-100639988",false,"NCT07600775","A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)","An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of untreated latent tuberculosis infection (LTBI)\n* Has no symptoms of active tuberculosis (TB)\n* Has never received treatment for TB or LTBI\n* Other than having LTBI, is in good health\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of LTBI made in the context of an outbreak\u002Fcontact-tracing investigation\n* Has a current or anticipated immunocompromised state\n* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases\n* Has a history of cancer (malignancy)\n* Has a history of active TB\n* Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus","ALL","18 Years","60 Years",{"count":42,"type":43},14,"ESTIMATED","INTERVENTIONAL",[46],"PHASE1","Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI).\n\nThe main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.",[49,50],"Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis","NOT_YET_RECRUITING","2026-06-30",{"date":54,"type":55},"2026-07-02","ACTUAL",{"date":57,"type":43},"2026-07-20",{"date":59,"type":43},"2027-01-19",{"name":5,"class":6}]